CING (Cingulate) Short Interest


CING Cingulate Inc CING
36 GF Score
Price $5.27
! 1 Warning Sign
View Full Analysis

What is Cingulate Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CING vs IMA, MCRB, PLRX: Short Interest Comparison

For the Biotechnology subindustry, Cingulate's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cingulate Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cingulate's Short Interest distribution charts can be found below:

* The bar in red indicates where Cingulate's Short Interest falls into.


CING
36GF Score
Cingulate Inc CING
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cingulate Business Description

Address 1901 West 47th Place, Kansas, KS, USA, 66205
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
36GF Score

Get the complete analysis for CING

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.27
Price